Denali Therapeutics Inc. 4

Nancy Thornberry sold a total of 11,439 shares of Denali Therapeutics Inc. common stock on September 2, 2026, for approximately $261,000 in open-market transactions under a Rule 10b5-1 plan.

On September 2, 2026, insider Nancy Thornberry executed two open-market sales of Denali Therapeutics Inc. common stock under a pre-arranged Rule 10b5-1 trading plan. She sold 10,824 shares at a weighted average price of approximately $22.85 per share (within a $22.54–$23.52 range) and an additional 615 shares at a weighted average price of approximately $23.74 per share (within a $23.59–$23.85 range), for total proceeds of roughly $261,000. Following these transactions, she directly held 19,686 shares of common stock, including 6,408 unvested RSUs, implying a remaining equity stake valued at about $467,000 based on the reported sale prices.

Filing Facts

CIK

1714899

Ticker

DNLI

Form

4

Source Type

fda

Accession

0001797826-26-000006

Alert Tier

5